{"disease":{"id":"sinusitis","name":"Sinusitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":14,"pipeline_drug_count":0,"trial_count":13},"drugs":{"marketed":[{"drug_id":"dupilumab","indication_name":"Chronic sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dupixent","generic_name":"DUPILUMAB","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Interleukin-4 receptor subunit alpha","drug_class":"Interleukin-4 Receptor alpha Antagonist [EPC]","quality_score":62,"revenue":"14600","mechanism":"Dupixent blocks the interleukin-4 receptor, a key player in the immune system's inflammatory response."},{"drug_id":"azithromycin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zithromax","generic_name":"azithromycin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor","drug_class":"Macrolide antibiotic (azalide)","quality_score":67,"revenue":"399","mechanism":"Macrolide antibiotic that binds the 50S ribosomal subunit, inhibiting bacterial protein synthesis with an exceptionally long tissue half-life."},{"drug_id":"fusidic-acid","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"fusidic-acid","indication_name":"Sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"doxycyclin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxycyclin","company_name":"Bulovka Hospital","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"doxycyclin","indication_name":"Sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxycyclin","company_name":"Bulovka Hospital","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"meticillin","indication_name":"Sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metacillin","generic_name":"meticillin","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"meticillin","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"amoxycillin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxycillin","company_name":"King George's Medical University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"nafcillin-sodium","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nallpen In Plastic Container","generic_name":"NAFCILLIN SODIUM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"cefpodoxime","indication_name":"Acute maxillary sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefpodoxime Proxetil","generic_name":"CEFPODOXIME","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"nafcillin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nallpen In Plastic Container","generic_name":"NAFCILLIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ampicillin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"ampicillin","indication_name":"Sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"moxifloxacin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelox","generic_name":"moxifloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"Fluoroquinolone antibiotic (fourth-generation)","quality_score":57,"revenue":null,"mechanism":"Fourth-generation fluoroquinolone with the broadest spectrum, covering gram-positive, gram-negative, anaerobic, and atypical organisms."},{"drug_id":"cloxacillin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methocillin S","generic_name":"CLOXACILLIN","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"cloxacillin","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cloxacillin","indication_name":"Sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methocillin S","generic_name":"CLOXACILLIN","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"cloxacillin","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"amphotericin-b","indication_name":"Sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"cefuroxime-axetil","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceftin","generic_name":"CEFUROXIME AXETIL","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":50,"revenue":null,"mechanism":"Ceftin works by inhibiting the bacterial enzyme responsible for cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"cefuroxime-axetil","indication_name":"Acute maxillary sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceftin","generic_name":"CEFUROXIME AXETIL","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":50,"revenue":null,"mechanism":"Ceftin works by inhibiting the bacterial enzyme responsible for cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"demeclocycline","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Demethylchlortetracycline","generic_name":"DEMECLOCYCLINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor beta","drug_class":"Tetracycline-class Antimicrobial","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"demeclocycline","indication_name":"Sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Demethylchlortetracycline","generic_name":"DEMECLOCYCLINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor beta","drug_class":"Tetracycline-class Antimicrobial","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"amoxicillin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amoxil","generic_name":"amoxicillin","company_name":"Generic (originally Beecham/GSK)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"Aminopenicillin (Beta-lactam antibiotic)","quality_score":56,"revenue":null,"mechanism":"Broad-spectrum aminopenicillin that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins."},{"drug_id":"erythromycin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"E-Mycin","generic_name":"erythromycin","company_name":"Generic (originally Abbott/Lilly)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Bile salt export pump, Cytochrome P450 1B1","drug_class":"Macrolide [EPC]","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Acute maxillary sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Acute Bacterial Sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"alatrofloxacin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ALATROFLOXACIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"alatrofloxacin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefprozil","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefzil","generic_name":"cefprozil","company_name":"Teva Pharmaceuticals USA","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial [EPC]","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"avelox","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avelox","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"meclocycline","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Meclan","generic_name":"MECLOCYCLINE","company_name":"Johnson And Johnson","drug_phase":"marketed","molecular_target":"","drug_class":"meclocycline","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"meclocycline","indication_name":"Sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Meclan","generic_name":"MECLOCYCLINE","company_name":"Johnson And Johnson","drug_phase":"marketed","molecular_target":"","drug_class":"meclocycline","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"atm-avi","indication_name":"Treatment of acute bacterial sinusitis (ABS) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of acute bacterial sinusitis (ABS) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"bacampicillin","indication_name":"Sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carampicillin","generic_name":"BACAMPICILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"bacampicillin","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"garenoxacin","indication_name":"Sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Geninax","generic_name":"GARENOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"garenoxacin","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"gatifloxacin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zymar","generic_name":"GATIFLOXACIN","company_name":"Allergan","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase, DNA gyrase subunit A","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"erythrocin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzamycin","generic_name":"Erythromycin Lactobionate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Macrolide","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefdinir","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Omnicef","generic_name":"CEFDINIR","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefpodoxime-proxetil","indication_name":"Acute maxillary sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantin","generic_name":"CEFPODOXIME PROXETIL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefpodoxime-proxetil","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantin","generic_name":"CEFPODOXIME PROXETIL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cefuroxime","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinacef","generic_name":"CEFUROXIME","company_name":"GSK","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Cephalosporin Antibacterial","quality_score":65,"revenue":null,"mechanism":"Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"cefuroxime","indication_name":"Acute maxillary sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinacef","generic_name":"CEFUROXIME","company_name":"GSK","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Cephalosporin Antibacterial","quality_score":65,"revenue":null,"mechanism":"Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"clavulanic-acid","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Augmentin 250","generic_name":"CLAVULANIC ACID","company_name":"Dr Reddys Labs Inc","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Acute maxillary sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Acute maxillary sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"amoxicillin-and-clavulanate","indication_name":"Sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxicillin and clavulanate","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Amoxicillin and Clavulanate Potassium is an antibacterial drug."},{"drug_id":"ciprofloxacin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Acute maxillary sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"clarithromycin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Biaxin","generic_name":"clarithromycin","company_name":"Generic (originally Abbott/AbbVie)","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Macrolide Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":"Clarithromycin is a macrolide antimicrobial drug."},{"drug_id":"clarithromycin","indication_name":"Acute maxillary sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Biaxin","generic_name":"clarithromycin","company_name":"Generic (originally Abbott/AbbVie)","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Macrolide Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":"Clarithromycin is a macrolide antimicrobial drug."},{"drug_id":"doxycycline","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"doxycycline","indication_name":"Sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"dicloxacillin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pathocil","generic_name":"DICLOXACILLIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Penicillin-class Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"levofloxacin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levaquin","generic_name":"levofloxacin","company_name":"Generic (originally Daiichi Sankyo/J&J)","drug_phase":"marketed","molecular_target":"CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2","drug_class":"Fluoroquinolone Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Levofloxacin is a fluoroquinolone antibacterial agent."},{"drug_id":"levofloxacin","indication_name":"Acute maxillary sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levaquin","generic_name":"levofloxacin","company_name":"Generic (originally Daiichi Sankyo/J&J)","drug_phase":"marketed","molecular_target":"CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2","drug_class":"Fluoroquinolone Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Levofloxacin is a fluoroquinolone antibacterial agent."},{"drug_id":"oxacillin","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bactocill In Plastic Container","generic_name":"OXACILLIN","company_name":"Apothecon","drug_phase":"marketed","molecular_target":"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"oxacillin","indication_name":"Sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bactocill In Plastic Container","generic_name":"OXACILLIN","company_name":"Apothecon","drug_phase":"marketed","molecular_target":"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Acute maxillary sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amoxicilli","indication_name":"Acute bacterial sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxicilli","company_name":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"minocyclin","indication_name":"Sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Minocyclin","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"minocycline","indication_name":"Sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Minocycline Hydrochloride","generic_name":"MINOCYCLINE","company_name":"Rempex","drug_phase":"marketed","molecular_target":"","drug_class":"Tetracycline-class Drug","quality_score":75,"revenue":null,"mechanism":"MINOCYCLINE works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"tezepelumab","indication_name":"Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tezspire","generic_name":"TEZEPELUMAB","company_name":"AstraZeneca / Amgen","drug_phase":"marketed","molecular_target":"","drug_class":"Thymic Stromal Lymphopoietin Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"rimegepant-75-mg","indication_name":"Acute treatment of chronic rhinosinusitis with and without nasal polyps","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75 MG","generic_name":"rimegepant-75-mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Calcitonin gene-related peptide (CGRP) receptor","drug_class":"CGRP receptor antagonist (gepant)","quality_score":25,"revenue":null,"mechanism":"Rimegepant selectively antagonizes the calcitonin gene-related peptide (CGRP) receptor to block migraine pain signaling."}],"offLabel":[],"totalMarketed":66,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03535558","title":"Fluoroquinolone Associated Disability","phase":"","overall_status":"COMPLETED","enrollment_count":239306,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT06105346","title":"Prevalence of ENT Diseseas","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Medical University of Graz","has_results":false},{"nct_id":"NCT05935683","title":"Rhinosinusitis Italian Network: the Italian Registry for Severe, Uncontrolled Chronic Rhinosinusitis","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Italian Academy of Rhinology","has_results":false},{"nct_id":"NCT04670172","title":"Real-Life Chronic Rhinosinusitis Outcome Registry","phase":"","overall_status":"RECRUITING","enrollment_count":4550,"lead_sponsor_name":"Change Accelerator in Respiratory Care","has_results":false},{"nct_id":"NCT07359287","title":"Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care","phase":"NA","overall_status":"RECRUITING","enrollment_count":4500,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT04447521","title":"Surveillance of Non-invasive Streptococcus Pneumoniae Infections in Belgium","phase":"","overall_status":"UNKNOWN","enrollment_count":3600,"lead_sponsor_name":"Sciensano","has_results":false},{"nct_id":"NCT07383350","title":"Improving Patient-centered Communication and Antibiotic Use With Information Sheets for Acute Respiratory Tract Infections: A Study Protocol","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1144,"lead_sponsor_name":"Research Unit for General Practice in Aalborg","has_results":false},{"nct_id":"NCT05127161","title":"Broad Implementation of Outpatient Stewardship","phase":"NA","overall_status":"COMPLETED","enrollment_count":1032,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT06970977","title":"CRS Questionnaire Validation Project","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"The European Forum for Research and Education in Allergy and Airway Diseases","has_results":false},{"nct_id":"NCT06231004","title":"Correlation Between the Microbiome and Type 2 Inflammatory Diseases of CRSwNP","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT00750750","title":"Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Study P02683)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":981,"lead_sponsor_name":"Organon and Co","has_results":false},{"nct_id":"NCT00751075","title":"Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Phase 3 Study)(Study P02692)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":981,"lead_sponsor_name":"Organon and Co","has_results":false},{"nct_id":"NCT04123405","title":"Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":944,"lead_sponsor_name":"Sandoz","has_results":true},{"nct_id":"NCT06501807","title":"BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":900,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT03584737","title":"Point-of-Care Immunoassay for Detection of Bacterial Sinusitis","phase":"","overall_status":"TERMINATED","enrollment_count":800,"lead_sponsor_name":"ENTvantage Dx","has_results":false},{"nct_id":"NCT03893227","title":"Prevalence of Nasal Hyperreactivity in Chronic Upper Airway Inflammation","phase":"","overall_status":"COMPLETED","enrollment_count":756,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT01018030","title":"Dose Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute Rhinosinusitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":741,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04959448","title":"Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":717,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT05061329","title":"The Nasal Microbiome and Its Importance in Disease","phase":"","overall_status":"RECRUITING","enrollment_count":619,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT05529784","title":"Dupilumab in the Treatment of Severe Uncontrolled CRSwNP: a Multicentre Observational Real-life Study (DUPIREAL)","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT02746042","title":"Sinupret Extract Coated Tablets in Chronic Rhinosinusitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":572,"lead_sponsor_name":"Bionorica SE","has_results":false},{"nct_id":"NCT06901297","title":"The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":552,"lead_sponsor_name":"Materia Medica Holding","has_results":false},{"nct_id":"NCT02898454","title":"Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":448,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT02720653","title":"Determinants of Olfactory Dysfunction in Chronic Rhinosinusitis","phase":"","overall_status":"UNKNOWN","enrollment_count":418,"lead_sponsor_name":"Oregon Health and Science University","has_results":false},{"nct_id":"NCT04851964","title":"Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":416,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT07424144","title":"An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":380,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT07200336","title":"Anti-IL-5 Therapy With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery for CRSwNP","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":360,"lead_sponsor_name":"Eye & ENT Hospital of Fudan University","has_results":false},{"nct_id":"NCT04998604","title":"EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":360,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT07125586","title":"Real-Time Diagnosis of Eosinophilic Nasal Polyps Using High-Sensitivity Spectroscopy","phase":"NA","overall_status":"RECRUITING","enrollment_count":353,"lead_sponsor_name":"The Affiliated Hospital of Qingdao University","has_results":false},{"nct_id":"NCT04703673","title":"Sinolpan® Pharmacy Non-interventional Study - Quality of Live","phase":"","overall_status":"COMPLETED","enrollment_count":350,"lead_sponsor_name":"Engelhard Arzneimittel GmbH & Co.KG","has_results":false},{"nct_id":"NCT03781804","title":"Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":332,"lead_sponsor_name":"Optinose US Inc.","has_results":true},{"nct_id":"NCT02340000","title":"Clinical Trial of the Treatment of Acute Sinusitis With Standard-dose Versus High-dose Amoxicillin/Clavulanate","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":315,"lead_sponsor_name":"Albany Medical College","has_results":true},{"nct_id":"NCT07290140","title":"Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Airiver Medical, Inc.","has_results":false},{"nct_id":"NCT04157335","title":"Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":295,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04131686","title":"NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis","phase":"","overall_status":"COMPLETED","enrollment_count":294,"lead_sponsor_name":"Boryung Pharmaceutical Co., Ltd","has_results":true},{"nct_id":"NCT06013241","title":"A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":288,"lead_sponsor_name":"Insmed Incorporated","has_results":false},{"nct_id":"NCT04664803","title":"Safety and Efficacy of Cefecin Tab. in Patients With Acute Sinusitis","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":284,"lead_sponsor_name":"Korea United Pharm. Inc.","has_results":false},{"nct_id":"NCT02912468","title":"A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":276,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT05248997","title":"Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":261,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02347943","title":"Global Sinus Surgery Registry","phase":"","overall_status":"TERMINATED","enrollment_count":252,"lead_sponsor_name":"Integra LifeSciences Corporation","has_results":true},{"nct_id":"NCT03478930","title":"An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":249,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06603935","title":"Harnessing Digital Medicine to Improve Allergic Rhinitis Management in Primary Care (DMAR)","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":240,"lead_sponsor_name":"QHSLab, Inc.","has_results":false},{"nct_id":"NCT07520162","title":"A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":230,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05157685","title":"Evaluation of the Efficacy of Azithromycin in Idiopathic Purulent Oedematous Sinusitis in Adults","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":230,"lead_sponsor_name":"Centre Hospitalier Intercommunal Creteil","has_results":false},{"nct_id":"NCT03960580","title":"Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":223,"lead_sponsor_name":"Optinose US Inc.","has_results":true},{"nct_id":"NCT05942222","title":"A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":220,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05925985","title":"Propel Drug-Eluting Sinus Stent Family Open Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":215,"lead_sponsor_name":"Medtronic","has_results":false},{"nct_id":"NCT06837051","title":"The Effect of Modified Olfactory Training on Postoperative Olfactory Dysfunction in Patients With CRS","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":213,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT07420257","title":"A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":212,"lead_sponsor_name":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06834360","title":"A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"Sanofi","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}